Novo Licenses Hengrui Once-Weekly Oral Incretin

Company Novo Nordisk; Jiangsu Hengrui Pharmaceuticals Event Type Exclusive License Modality Oral Small Molecule Asset HRS-1596 Target GLP-1 Receptor; GIP Receptor Disease Area Obesity; Type 2 Diabetes Summary Novo Nordisk licensed ex-China-region rights to Hengrui’s HRS-1596, a Phase 1-ready oral GLP-1/GIP dual-receptor agonist designed for…